Clinical Trial

A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-25
notable Primary completion pushed: 2024-12-01 -> 2025-10-17 2026-07-25
minor Completion pushed: 2025-08-31 -> 2025-10-17 2026-07-25
Trial Details
NCT Number NCT06137768
Lead Sponsor Chengdu Suncadia Medicine Co., Ltd.
Conditions Primary IgA Nephropathy
Enrollment 123 participants
Start Date 2023-12-19
Primary Completion 2025-10-17 (estimated)
Study Completion 2025-10-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-24